International Stem Cell (ISCO) EBITDA (2010 - 2026)
International Stem Cell's (ISCO) quarterly EBITDA came in at -$35000.0 in Q2 2026, down 120.96% year-over-year from $167000.0 in Q2 2025, and up 88.82% quarter-over-quarter from -$313000.0 in Q4 2025.
Powered by 
Analysis
International Stem Cell (ISCO) EBITDA (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported EBITDA for 17 consecutive years, with -$35000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA fell 120.96% year-over-year to -$35000.0 in Q2 2026; TTM through Jun 2026 was -$87000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at -$267000.0, down 292.65% from the prior year.
- EBITDA was -$35000.0 for Q2 2026 at International Stem Cell, up from -$313000.0 in the prior quarter.
- Over five years, EBITDA peaked at $167000.0 in Q2 2025 and troughed at -$424000.0 in Q4 2023.
- A 5-year average of -$71529.4 and a median of -$35000.0 in 2026 frame the typical range for EBITDA.
- Across the five-year window, EBITDA tumbled 9000.0% in 2024 and soared 204.44% in 2025, its largest moves.
- Over 5 years, EBITDA stood at $61000.0 in 2022, then sank by 795.08% to -$424000.0 in 2023, then soared by 112.03% to $51000.0 in 2024, then sank by 713.73% to -$313000.0 in 2025, then surged by 88.82% to -$35000.0 in 2026.
- The last three EBITDA figures came in at -$35000.0 (Q2 2026), -$313000.0 (Q4 2025), and $94000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 58.42 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -117.27 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -51.91 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 57.70 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -52.20 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -126.55 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 22.64 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 13.29 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 434,000.00 |
| 10 | International Stem Cell | 2.84 Mn | 1.75 Mn | 1.46 Mn | -35,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | -178,000.00 |
| Dec 31, 2023 | -424,000.00 |
| Sep 30, 2023 | -97,000.00 |
| Jun 30, 2023 | -144,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | -300,000.00 |
| Jun 30, 2022 | 31,000.00 |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | -323,000.00 |
| Sep 30, 2021 | -623,000.00 |
| Jun 30, 2021 | -406,000.00 |